Skip to main content

Table 5 Summary of Median Overall Survivals in the various studies included in the current review

From: Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients

   Overall survival (months)
   All patients Resected Not resected
Resectable Median (range) 18.2 (13–28) 30.0 (24.5–46) 10 (9–11)
  n 9 8 5
Borderline resectable Median (range) 19.2 (9.1–45) 27.4 (19.3–41.2) 12.9 (9–15.5)
  n 11 8 7
Locally advanced Median (range) 13.6 (7.3–32.5) 18.7 (14.4–24.9) 12.6 (8–19.7)
  n 28 8 7
BR + LA Median (range) 14.7 (10.6–47.2) 26 (13–47.4) 12.4 (8.8–17)
  n 16 11 9
All patients Median (range) 15.3 (7.3–47.2) 24.4 (11.7–47.4) 11.5 (5.7–19.7)
  n 63 39 32
Progression-free survival (months)
   All patients Resected Not resected
Resectable Median (range) 8.4 (6.2–10.4) 14.9 (8.4–23) 11*
  n 2 4 1
Borderline resectable Median (range) 9 (2.4–21.1) 15.4 (4.7–23.2) 2.1*
  n 6 6 1
Locally advanced Median (range) 9.3 (4–17.6) 12.9 (9.6–22.5) 5.7 (4–8)
  n 20 6 3
BR + LA Median (range) 9.9 (6.5–27.4) 12.5 (9–19.7) 7.5 (7.1–7.6)
  n 9 4 2
All patients Median (range) 9.3 (2.4–27.4) 12.9 (4.7–23.2) 5.8 (2.1–11)
  n 31 20 7
  1. *Only one observation. n number of studies reporting the outcome. Values in parenthesis indicate ranges